# Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT07559045** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Zunyi Medical University** · enrollment: 92 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy)
- **DRUG:** Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy)

## Key facts

- **NCT ID:** NCT07559045
- **Lead sponsor:** Second Affiliated Hospital of Zunyi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-06-30
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07559045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07559045, "Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07559045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*